The metabolic drugs reshaping waistlines are now reshaping the food supply chain. A 5.3% reduction in grocery spending among GLP-1 users signals the beginning of a structural demand shift that food manufacturers are only beginning to price into strategy.
Alternative protein has reached price parity with conventional protein in specific categories — and the driver is now cost and convenience, not environmental concern, which changes everything about the transition's trajectory.
Regulatory signals in Brazil, Colombia, and the UK suggest ultra-processed food is approaching an inflection analogous to tobacco in the 1980s — the scientific consensus is consolidating and the political coalition is forming.
Metabolic disease — obesity, type 2 diabetes, cardiovascular disease, fatty liver — now accounts for the majority of US healthcare spending. The dietary signals that predicted this have been visible for decades.